Results 61 to 70 of about 6,419 (213)
Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.ABSTRACT Objective To assess whether antivirals are associated with a reduced incidence of uveitis following COVID‐19. Methods We conducted a multi‐institutional, population‐based retrospective cohort study of adults (≥ 18 years) diagnosed with COVID‐19 between 2022 and 2024. Patients who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir)
Hou‐Ting Kuo +14 more
wiley +1 more source
BMC MedicineBackground Paxlovid has been shown to be effective in reducing mortality and hospitalization rates in patients with coronavirus disease 2019 (COVID-19).
Weijie Wang +5 more
doaj +1 more source
The Clinical Respiratory Journal, Volume 20, Issue 5, May 2026.This case reports a 25‐year‐old allo‐HCT recipient with severe HCoV‐OC43 pneumonia who responded well to off‐label nirmatrelvir/ritonavir. It is the first such report that show the drug may benefit immunocompromised patients with this infection, though further studies are needed to confirm efficacy.
Mingzhou Zhang +5 more
wiley +1 more source
International Journal of Infectious DiseasesIntroduction: COVID-19 poses a severe threat to high-risk populations, such as the elderly and those with incomplete vaccination. Despite the availability of treatments like Paxlovid and Molnupiravir, their relative effectiveness in preventing severe ...
Dr Yi-hsuan Chen +4 more
doaj +1 more source
Clinical and Translational Science, Volume 19, Issue 5, May 2026.ABSTRACT In accordance with the Centers for Disease Control and Prevention recommendations, pregnant women and those with a recent pregnancy (i.e., lactating) are considered at high risk of developing severe COVID‐19 and qualify for treatment with nirmatrelvir/ritonavir.
Jacqueline Gerhart +7 more
wiley +1 more source
Paxlovid reduces the 28-day mortality of patients with COVID-19: a retrospective cohort study
BMC Infectious DiseasesPurpose In this study, we aim to explore the efficacy of paxlovid on reducing mortality of COVID-19 patients in clinical setting, especially whether paxlovid modifies the risk of death in these severe and critical patients.
Kaican Zong +9 more
doaj +1 more source
ChemMedChem, Volume 21, Issue 7, 14 April 2026.A SAR study led to the identification of new 2‐phenylquinoline‐based derivatives that exhibit anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) activity by acting as ATP‐competitive inhibitors of nonstructural protein 13 (nsp13) helicase.
Giada Cernicchi +24 more
wiley +1 more source
Risks of paxlovid in a heart transplant recipient
The Journal of Heart and Lung Transplantation, 2023 The burden of morbidity and mortality from SARS-CoV-2 infection is especially significant in heart transplant patients who are at higher risk for poor outcomes owing to immunosuppression, blunted response to vaccination, and multiple comorbid conditions.
Kristin Stawiarski +3 more
openaire +2 more sources
Structure‐ and Ligand‐Based Discovery of Novel 3‐Chymotrypsin‐Like Protease Nonpeptidomimetic Hits
ChemMedChem, Volume 21, Issue 7, 14 April 2026.A multistep virtual screening cascade, integrating shape‐based, ensemble docking, and quantitative structure–activity relationship (QSAR) models, was employed to screen 1.5 million compounds. This funnel identified a novel 3‐chymotrypsin‐like protease (3CLpro) inhibitor, LabMol‐499, which was experimentally validated using a Förster Resonance Energy ...
Sabrina Silva‐Mendonça +14 more
wiley +1 more source
Medicine Advances, 2023 The infection of the coronavirus disease 2019 (COVID‐19) is often accompanied by pneumonia with both high incidence and mortality. Paxlovid is commonly prescribed in patients with mild and normal pneumonia within 5 days from the symptom onset. Herein, we
Qiang Li +15 more
doaj +1 more source